Fluzoparib+Apatinib

DRUG3 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Xiaohua Wu MD, Guangxi Medical University

Conditions

Fallopian Tube CancerHigh Grade Serous Adenocarcinoma of OvaryOvarian CancerPrimary Peritoneal CarcinomaRelapsed Ovarian Cancer

Phase 2

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

CompletedNCT04517357

Jiangsu HengRui Medicine Co., Ltd.Relapsed Ovarian Cancer

Start: 2020-10-16End: 2024-11-01Updated: 2025-02-24

Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

Not yet recruitingNCT05479487

Xiaohua Wu MDRelapsed Ovarian Cancer

Start: 2022-08-01End: 2026-09-01Target: 132Updated: 2022-07-29

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Guangxi Medical UniversityFallopian Tube Cancer, High Grade Serous Adenocarcinoma of Ovary, Ovarian Cancer +1

Start: 2023-12-10End: 2026-01-10Target: 80Updated: 2023-12-07

Related Papers

Fuzuloparib in combination with apatinib versus fuzuloparib alone for recurrent ovarian cancer: a randomized, open-label, phase 2 trial

Journal of Ovarian Research2026-08-15